Ge\u00e7en ay ABD G\u0131da ve \u0130la\u00e7 Dairesi\u2019nden (FDA) tam onay alan Leqembi, Alzheimer\u2019\u0131n erken evrelerindeki hastalarda hastal\u0131\u011f\u0131n ilerlemesini yava\u015flatt\u0131\u011f\u0131 kan\u0131tlanm\u0131\u015f ilk tedavi olmu\u015ftu.<\/p>\n
Hastal\u0131\u011f\u0131n, ABD h\u00fck\u00fcmetinin 65 ya\u015f ve \u00fcst\u00fc i\u00e7in sundu\u011fu sa\u011fl\u0131k sigortas\u0131 Medicare kapsam\u0131ndaki yakla\u015f\u0131k 6,5 milyon ki\u015finin \u00e7o\u011funu etkiledi\u011fi san\u0131l\u0131yor.<\/p>\n
Miami \u00dcniversitesi Miller T\u0131p Fak\u00fcltesi Alzheimer ara\u015ft\u0131rma program\u0131 ba\u015fkan\u0131 Dr. James Galvin, yeni ilaca olan ilgiyi \u201cHastalar s\u0131raya giriyor. Tedavi olmak istiyorlar, ancak hemen m\u00fcdahale etmek zor\u201d s\u00f6zleriyle aktard\u0131.<\/p>\n
Leqembi\u2019yi birka\u00e7 ay i\u00e7inde piyasaya s\u00fcrmeyi planlayanlar aras\u0131nda Minnesota eyaletinin Rochester kentindeki Mayo Clinic, Chicago\u2019daki Northwestern Memorial Hastanesi ve Los Angeles\u2019taki Cedars-Sinai Hastanesi yer al\u0131yor. Cleveland Clinic ve Utah\u2019\u0131n Intermountain sa\u011fl\u0131k sistemi ise hen\u00fcz ilac\u0131 sunmaya ba\u015flamad\u0131klar\u0131n\u0131 s\u00f6yledi.<\/p>\n
Eisai ve Biogen taraf\u0131ndan payla\u015f\u0131lan bir elektronik postada bir\u00e7ok doktorun Leqembi\u2019yi re\u00e7ete etti\u011fi ve al\u0131m\u0131n beklendi\u011fi gibi ilerlemeye devam etti\u011fi belirtildi.<\/p>\n
MEDICARE \u0130LA\u00c7 MASRAFLARININ \u00c7O\u011eUNU KAR\u015eILAYACAK<\/strong><\/p>\n Leqembi, beyindeki beta-amiloid adl\u0131 yap\u0131\u015fkan proteini hedef al\u0131p temizlemek i\u00e7in tasarlanm\u0131\u015ft\u0131r. FDA\u2019n\u0131n onay vermesinin ard\u0131ndan Medicare, ilac\u0131n masraf\u0131n\u0131 b\u00fcy\u00fck \u00f6l\u00e7\u00fcde kar\u015f\u0131lama s\u00f6z\u00fc verdi. Medicare ayr\u0131ca tedavi adaylar\u0131 i\u00e7in \u00f6nerilen beyin g\u00f6r\u00fcnt\u00fcleme y\u00f6ntemi \u00fczerindeki on y\u0131l s\u0131n\u0131rlamas\u0131n\u0131 hafifletmeyi d\u00fc\u015f\u00fcn\u00fcyor.<\/p>\n Wall Street uzmanlar\u0131, Eisai ve Biogen\u2019in ilac\u0131 piyasaya s\u00fcrmesinin \u00f6deme ve te\u015fhis de\u011ferlendirmesindeki sorunlar nedeniyle yava\u015flamas\u0131n\u0131 bekliyor. Merkezi Tokyo\u2019daki Eisai \u015firketi 2024 y\u0131l\u0131n\u0131n Mart ay\u0131na kadar 10 bin ki\u015finin ve 2026\u2019ya kadar 100 bin ki\u015finin ilaca eri\u015fmesini bekliyor.<\/p>\n Leqembi\u2019nin piyasaya s\u00fcr\u00fclmesi i\u00e7in hastalar\u0131n tedaviye elveri\u015fli olup olmad\u0131\u011f\u0131n\u0131 anlamak i\u00e7in \u00e7e\u015fitli testler yap\u0131lmas\u0131 gerekiyor. Bunlar aras\u0131nda hastalar\u0131n ilac\u0131n etki etti\u011fi erken safhada olduklar\u0131ndan emin olmak i\u00e7in yap\u0131lan bili\u015fsel testler, yan etki risklerinin anla\u015f\u0131lmas\u0131 i\u00e7in yap\u0131lan genetik testler ve Leqembi\u2019nin m\u00fccadele etti\u011fi amiloid adl\u0131 proteinin v\u00fccuttaki varl\u0131\u011f\u0131n\u0131 do\u011frulamak i\u00e7in yap\u0131lan beyin taramalar\u0131 ile omurilik s\u0131v\u0131s\u0131 testi yer al\u0131yor.<\/p>\n Leqembi\u2019nin beyin \u015fi\u015fmesi veya kanamas\u0131 gibi yan etki risklerine kar\u015f\u0131 hastalar\u0131n ayr\u0131ca tedaviden \u00f6nce bir kez ve tedavi s\u0131ras\u0131nda birka\u00e7 kez MRI taramas\u0131na girmesi gerekiyor. Kan p\u0131ht\u0131la\u015fmas\u0131n\u0131 \u00f6nleyen ila\u00e7lar\u0131n kullan\u0131lmas\u0131 da beyinde kanama riskini art\u0131rabilir.<\/p>\n Mayo Clinic doktorlar\u0131ndan David Knopman, beyindeki \u015fi\u015fme \u00f6zellikle hafif oldu\u011funda bunu MRI\u2019da fark etmenin zor oldu\u011funu ve \u00f6zel e\u011fitim gerektirdi\u011fini s\u00f6yledi.<\/p>\n Duke Haf\u0131za Bozukluklar\u0131 Program\u0131 Ba\u015fkan\u0131 Dr. Kim Johnson ise 6 Temmuz\u2019da FDA\u2019den tam onay almas\u0131ndan \u00f6nce, Kuzey Carolina\u2019daki Duke \u00dcniversitesi Sa\u011fl\u0131k Sistemi\u2019nin ilac\u0131 cepten \u00f6deyen 16 hastada kullanmaya ba\u015flad\u0131\u011f\u0131n\u0131 belirtti. Johnson, sistemin bekleme listesinde 100-150 te\u015fhis edilmi\u015f Medicare hastas\u0131 oldu\u011funu, ancak bunlar\u0131n tedaviden \u00f6nce yeniden tetkiklerden ge\u00e7meleri gerekece\u011fini s\u00f6yl\u00fcyor. Pennsylvania \u00dcniversite Hastanesi\u2019nde de klinik uygulaman\u0131n bu ay ba\u015flamas\u0131 ve ilk inf\u00fczyonun \u00f6n\u00fcm\u00fczdeki birka\u00e7 g\u00fcn i\u00e7inde yap\u0131lmas\u0131 bekleniyor. Yeni Alzheimer ilac\u0131 Leqembi\u2019nin, hastalara umut olabilece\u011fi ve Alzheimer hastal\u0131\u011f\u0131n\u0131n tedavisinde \u00f6nemli bir ad\u0131m olarak kabul edilebilece\u011fi d\u00fc\u015f\u00fcn\u00fcl\u00fcyor.<\/p>\n","protected":false},"excerpt":{"rendered":" ABD’de be\u015f b\u00fcy\u00fck sa\u011fl\u0131k sistemi, Japon ila\u00e7 firmas\u0131 Eisai ve Amerikal\u0131 orta\u011f\u0131 Biogen taraf\u0131ndan \u00fcretilen gelecek vadeden yeni Alzheimer ilac\u0131 Leqembi’yi, bir ya da iki ay i\u00e7inde piyasaya sunmaya haz\u0131rlan\u0131yor.<\/p>\n","protected":false},"author":1,"featured_media":109398,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[30],"tags":[165,1132,376],"class_list":["post-109397","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-saglik","tag-beyin","tag-ilaci","tag-tedavi"],"_links":{"self":[{"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/posts\/109397","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haberulus.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=109397"}],"version-history":[{"count":1,"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/posts\/109397\/revisions"}],"predecessor-version":[{"id":109399,"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/posts\/109397\/revisions\/109399"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haberulus.net\/index.php?rest_route=\/wp\/v2\/media\/109398"}],"wp:attachment":[{"href":"https:\/\/haberulus.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=109397"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haberulus.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=109397"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haberulus.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=109397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}